This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BLUE bluebird bio (BLUE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock About bluebird bio Stock (NASDAQ:BLUE) 30 days 90 days 365 days Advanced Chart Get bluebird bio alerts:Sign Up Key Stats Today's Range$4.97▼$4.9750-Day Range$3.29▼$5.0052-Week Range$3.20▼$25.10VolumeN/AAverage Volume452,966 shsMarket Capitalization$48.67 millionP/E RatioN/ADividend YieldN/APrice Target$44.60Consensus RatingHold Company Overview bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts. Read More bluebird bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreBLUE MarketRank™: bluebird bio scored higher than 39% of companies evaluated by MarketBeat, and ranked 1378th out of 1,841 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus Ratingbluebird bio has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst Coveragebluebird bio has received no research coverage in the past 90 days.Read more about bluebird bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for bluebird bio are expected to grow in the coming year, from ($27.25) to ($11.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of bluebird bio is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of bluebird bio is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratiobluebird bio has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about bluebird bio's valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for BLUE. Dividend0.0 / 5Dividend StrengthN/A Dividend Yieldbluebird bio does not currently pay a dividend.Dividend Growthbluebird bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for BLUE. News and Social Media1.1 / 5News SentimentN/A Search Interest2 people have searched for BLUE on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added bluebird bio to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, bluebird bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.40% of the stock of bluebird bio is held by insiders.Percentage Held by Institutions87.43% of the stock of bluebird bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about bluebird bio's insider trading history. Receive BLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter. Email Address BLUE Stock News HeadlinesPetri Dish: ProFound’s Novartis deal worth $750M, Dyne secures debtJuly 3, 2025 | bizjournals.combluebird bio Strengthens Leadership Team With New AppointmentsJuly 1, 2025 | finance.yahoo.comElon Leaves DOGE? Here’s What’s Next…Early investors in Tesla saw 30,000% returns. SpaceX? Similar story. Now, Elon Musk is going all-in on something even bigger: artificial superintelligence. He’s calling it the next evolution of AI—and insiders are already calling it “AI 2.0.” The project is advancing quickly, and a key update could be announced as early as this summer. You can’t invest directly in Elon’s new tech—but there’s a backdoor way in. | Paradigm Press (Ad)Essential Pharma strengthens Board with the appointment of Nicola Heffron as Non-Executive DirectorJune 25, 2025 | finance.yahoo.comCarlyle, SK Capital close deal for bluebird bio, injecting capital for commercial expansionJune 2, 2025 | bizjournals.combluebird bio Announces Completion of Acquisition by Carlyle and SK CapitalJune 2, 2025 | businesswire.combluebird bio, Inc. (BLUE) Nears Acquisition by Carlyle and SK CapitalJune 1, 2025 | finance.yahoo.combluebird bio, Inc. (BLUE) Nears Acquisition by Carlyle and SK CapitalMay 30, 2025 | insidermonkey.comSee More Headlines BLUE Stock Analysis - Frequently Asked Questions How were bluebird bio's earnings last quarter? bluebird bio, Inc. (NASDAQ:BLUE) released its earnings results on Tuesday, November, 7th. The biotechnology company reported ($13.20) earnings per share for the quarter, beating analysts' consensus estimates of ($13.80) by $0.60. bluebird bio's revenue for the quarter was up 17364.8% on a year-over-year basis. Read the conference call transcript. When did bluebird bio's stock split? bluebird bio's stock reverse split before market open on Friday, December 13th 2024.The 1-20 reverse split was announced on Wednesday, December 4th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are bluebird bio's major shareholders? Top institutional investors of bluebird bio include FNY Investment Advisers LLC. Insiders that own company stock include Andrew Obenshain, Nick Leschly, Jason Cole, Thomas J Klima, Richard A Colvin and Christopher Krawtschuk. View institutional ownership trends. What other stocks do shareholders of bluebird bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that bluebird bio investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings11/07/2023Today8/05/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BLUE CIK1293971 Webwww.bluebirdbio.com Phone(339) 499-9300FaxN/AEmployees520Year FoundedN/APrice Target and Rating Average Price Target for bluebird bio$44.60 High Price Target$120.00 Low Price Target$5.00 Potential Upside/Downside+797.4%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($41.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$211.91 million Net Margins-565.74% Pretax Margin-551.41% Return on Equity-322.46% Return on Assets-53.17% Debt Debt-to-Equity Ratio0.37 Current Ratio0.51 Quick Ratio0.33 Sales & Book Value Annual Sales$103.95 million Price / Sales0.47 Cash FlowN/A Price / Cash FlowN/A Book Value$35.59 per share Price / Book0.14Miscellaneous Outstanding Shares9,792,000Free Float9,586,000Market Cap$48.67 million OptionableOptionable Beta0.27 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:BLUE) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share bluebird bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.